AAQ,
This is from the UK Government press release.
“Molnupiravir has been authorised for use in people who have mild to moderate COVID-19 and at least one risk factor for developing severe illness. Such risk factors include obesity, older age (>60 years), diabetes mellitus, or heart disease.”
So apparently they are also initially reserving it for those with at least one risk factor. I assume that with time, the recommendations will be adjusted based on the data.